India is emerging as an epicenter of the dengue disease burden with an estimated 20-40 million clinically apparent infections per year. As currently there is no vaccine available in India and hence, there is a need for an affordable vaccine for the prevention of Dengue infection. The National Biopharma Mission is committed to support development of vaccine candidates for effective management of dengue.

Vaccine candidate

Name of grantee

Development Phase Supported

Environmental and Health Risk Management Plan (EHRMP)

Live attenuated

Indian Immunologicals Limited

Pre-clinical and Phase I CT material generation

Click Here

Sun Pharmaceutical Industries Limited (SPIL)


Sun Pharma Advanced Research Company Ltd (SPARC)

 Toxicity Studies

Click Here



Click Here